68Ga-EV203 imaging for blood cancers
Part of Blood & lymphatic, Cancer clinical trials.
This trial uses a special imaging agent called 68Ga-EV203 to see where certain blood cancers (multiple myeloma, non-Hodgkin lymphoma, or acute myeloid leukemia) are located in the body. It helps doctors understand how the agent spreads and how safe it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You need to be able to lie still on a scanner bed for about 30 minutes.
- You must have a confirmed diagnosis of multiple myeloma, non-Hodgkin lymphoma, or acute myeloid leukemia.
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study.
- You must not have had any other cancer treatment within the last 2 weeks, or radiation within the last 8 weeks.
- You must not have a fear of enclosed spaces (claustrophobia) that would prevent you from having the scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new PET scan method (using a special tracer called 18F-Pentixafor) to see if it can better find and track blood cancers. It may help your doctors get more detailed images with less radiation.
This study tests a new imaging agent called 64Cu-LLP2A to see if it can better detect certain blood cancers like multiple myeloma and low-grade lymphomas. It aims to find tumors more clearly than standard scans, which could help your doctor plan the best care for you.
This study tests a new type of PET scan called 68Ga-Pentixafor to see how well it finds and stages blood cancers (like non-Hodgkin lymphoma and myeloma). It will compare this new scan to the standard FDG-PET scan. If you join, you may get more accurate information about your cancer.
This early (Phase 1) study tests how a special scan works in people with relapsed or hard-to-treat leukemia types. The scan uses a tracer called 18F FLT, and the study looks to see if it can be done safely (without sedation) and how it relates to treatment.
This study tests a new imaging agent that may help doctors see multiple myeloma more clearly. It uses a special radioactive tracer that targets a protein found on myeloma cells, which could improve diagnosis and monitoring of the disease.
This study tests a new PET imaging agent called [68Ga]Ga-ELI411 to help see tumors more clearly. It is for adults with solid tumors who are already scheduled for a standard PET scan, and may help doctors better understand and manage their cancer.
Hear when a new Hematological Malignancies B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.